Department of Internal Medicine, French Vasculitis Study Group, UPRES Recherche Clinique et Thérapeutique, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, 125 route de Stalingrad, 93000 Bobigny, France
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods. Ten patients refractory to corticosteroids and at least one immunosuppressant and who had persistently active disease or a new flare were included. Seven had Wegener's granulomatosis, two had rheumatoid arthritis-associated vasculitis and one had cryoglobulinaemia with mean duration of 9.1, 21.5 and 17 yr. They received infliximab (5 mg/kg) on days 1, 14, 42 and then every 8 weeks. Immunosuppressants were stopped between days 0 and 42 for eight patients, while the steroid dose was maintained or lowered. The treatment response was evaluated clinically with the Birmingham Vasculitis Activity Score 2000 (BVAS).
Results. Complete or partial remission was observed in all patients. The mean BVAS at entry was 9.1 (range 415) and had declined to 1.9 (range 04) by day 42 and 1.3 (range 04) at 6 months; BVAS of 0 was recorded for four patients on day 42 and for five at 6 months. The only adverse effect was cutaneous eruption in two patients.
Conclusion. Anti-TNF- successfully induced prompt symptomatic responses in patients with systemic vasculitis not responding to conventional treatment. Infliximab was well tolerated during the short-term follow-up.
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Vasculitides met the American College of Rheumatology criteria for WG [3] and rheumatoid arthritis (RA)-associated vasculitis or were biopsy-proven. Patients also satisfied the criteria for vasculitides according to the Chapel Hill nomenclature [4]. At the time when anti-TNF- Ab therapy was initiated, all the patients had persistent active vasculitis or were experiencing a new flare.
Study protocol
Patient inclusion criteria were: (i) failure to respond to CS and at least one immunosuppressant [cyclophosphamide (CYC), azathioprine (AZA), methotrexate (MTX) or mycophenolate mofetil (MMF)] or (ii) CYC had to have been discontinued because of side-effects. Another patient with mixed cryoglobulinaemia (MC)-associated vasculitis was enrolled because poor venous access contraindicated the continuation of plasma exchanges (PE), which had previously been effective.
To evaluate the efficacy of anti-TNF- Ab in combination with CS (dose range 565 mg/day), immunosuppressants were stopped at day 0, except for two patients with severe disease who received CYC (patient 8) or MTX and MMF (patient 9). The CS dose was maintained or lowered when possible. Patients received anti-TNF-
Ab intravenously at 5 mg/kg on days 0, 14 and 42 and then every 8 weeks. Immunosuppressants were reintroduced on day 42. The choice of immunosuppressant was based on the prior responses (ineffective, toxic) to the drugs administered previously. For example, when a patient had relapsed under MTX, we subsequently chose another immunosuppressant, e.g. AZA. Treatment with anti-TNF-
Ab could be discontinued during the following weeks if the flare was controlled by the first three infusions. Patients were seen on days 0, 14 and 42, and at 2 and 6 months or more often if necessary.
Disease assessment
At each visit, we collected data on clinical symptoms, response to therapy and possible side-effects. Biological analyses and radiological examinations were performed according to each patient's clinical symptoms. The treatment response was evaluated clinically and with the Birmingham Vasculitis Activity Score 2000 (BVAS) determined on day 42 and at 6 months [5]. Because of the diversity of the vasculitides included in this pilot trial, we used the BVAS 2000 and not the modified BVAS for WG [6]. Responses were defined as follows: complete remission (CR) when no clinical and biological signs of activity were present at 6 months with BVAS=0; partial remission (PR) when the clinical and biological responses were incomplete with BVAS >0 but inferior to the entry score; sequelae were defined as clinical manifestations that persisted and remained stable and for which no further improvement was expected.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Prior immunosuppressant treatments prescribed before anti-TNF- Ab were CYC in nine patients, MTX in six, AZA in three, MMF in two and immunoglobulins in three. Patient 1 had also received D-penicillamine and cyclosporin for severe RA, patient 3 had also taken sulphasalazine and mesalazine for WG with colon involvement, and patient 10 had also received interferon
for MC-associated vasculitis. Patients 7 and 10 also underwent PE for refractory WG and MC-associated vasculitis respectively. The baseline data and outcome are detailed in Table 1
.
Clinical manifestations of vasculitides present at the time of anti-TNF- Ab initiation were: inflammatory syndrome (n=5); upper respiratory tract involvement (n=4); lung involvement (n=4); eye involvement (n=3); arthritis (n=2); skin ulcers (n=2); glomerulonephritis with hypertension, proteinuria, renal insufficiency and microscopic haematuria without biopsy (n=1); colitis due to WG proven histologically (n=1); stroke (n = 1); dura mater infiltration with hypophyseal involvement, revealed by diabetes insipidus (n=1); worsening mononeuritis multiplex (n=1); worsening pyoderma gangrenosum (n=1 WG patient). The mean BVAS at entry was 9.1 (median 8, range 415).
Immunosuppressants were reintroduced after day 42: AZA for six patients; MMF for three; MTX for two; and left unchanged for patient 9, who received a combination of CYC, MMF and MTX (Table 1).
Outcome and response to treatment
All patients had improved on day 42 and improvement persisted at 6 months. For 4/10 patients, symptom attenuation was obtained within 2 weeks (Table 1).
The mean BVAS (Table 2 and Fig. 1
) had declined to 1.9 (median 1.5, range 04) on day 42 (79% decrease) and 1.3 (median 0.5 range 04) at 6 months (85% decrease). Anti-TNF-
Ab could be stopped in four patients (patients 4, 5, 6 and 8), because of good efficacy; their mean BVAS was 8.25 (median 8, range 612) on day 0, 0.75 (median 0, range 03) on day 42 (90% decrease) and 0.5 (median 0, range 02) at 6 months (93% decrease).
|
|
The CS dose was lowered for five patients, maintained for three, stopped for one on day 42, and increased for patient 10, who developed purpura and skin ulcers. CS were decreased for five patients, maintained for three and stopped for two at 6 months, and were not increased. Mean prednisone doses (mg) on day 0, day 42 and at 6 months were respectively 23.4 (range 565), 19.5 (050) and 10.1 (025) (Fig. 2). Three of five patients who decreased and 3/3 patients who maintained their CS dose at 6 months were receiving anti-TNF-
Ab. Patients 4 and 5, who stopped CS, were also able to discontinue anti-TNF-
Ab.
|
At 6 months, five patients were in CR and five in PR. Six patients had sequelae: mononeuritis multiplex (patients 2, 8 and 10); residual effects of a stroke (patient 8); persistent dyspnoea due to bronchial stenosis (patient 4); sinus osseous destruction (patient 9); and hypophysitis with diabetes insipidus (patient 6).
Side-effects
No major side-effects were observed. A mild transient cutaneous eruption was observed only after the first anti-TNF- Ab infusion in patient 4 and only at 6 months in patient 10, for whom anti-TNF-
Ab was discontinued. No infection was noted.
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
There is some evidence that could explain the efficacy of anti-TNF- in vasculitis, particularly WG. TNF-
is a major proinflammatory cytokine. Plasma TNF-
is elevated in patients with active WG [12]. During activation of polymorphonuclear neutrophils (PMN) by TNF-
, intracellular proteinase 3 (PR3) is transported to the cell surface, where it can bind circulating ANCA [13].
Phagocytosis of PR3ANCA-opsonized PMN by macrophages leads to the release of TNF- and other proinflammatory mediators and could contribute to the priming and recruitment of more PMN, leading to self-perpetuating inflammation [14].
This open pilot study, lasting 6 months, demonstrated that anti-TNF- Ab therapy provided clinical benefit for patients who had active vasculitis (including WG and RA) and did not respond to immunosuppressants and CS. Responses to anti-TNF-
Ab were obtained within 2 months and were often observed after the first month. The beneficial effects persisted at 6 months in 8/9 patients. The patient with MC improved markedly after the first infusion but relapsed at 4 months with mild cutaneous ulcers and purpura. This outcome is not surprising in this long-standing multi-relapsing disease.
The BVAS had decreased by 79% from the baseline on day 42 and by 85% at 6 months. In parallel, it was possible to taper CS by 16.6% on day 42 and by 56.8% at 6 months. Under CS and anti-TNF- Ab therapy, symptoms became attenuated or disappeared (Table 1
) in all patients.
The following symptoms were considered sequelae: mononeuritis multiplex, stroke, hypophyseal involvement and dyspnoea due to bronchial stenosis. However, it is sometimes difficult to differentiate between persistent signs of active vasculitis and their definitive residual consequences, both clinically and for the determination of BVAS. The latter requires the retrospective assessment of the patient's disease course from entry onwards in order to distinguish between PR and sequelae. In addition, patient 9's seizure at 4 months was not considered in the 6-month BVAS because it had not occurred during the previous 28 days. Patients who discontinued anti-TNF- Ab had a lower BVAS at baseline (mean BVAS 8.25 vs 9.1), whereas patients 9 and 10, who relapsed, had a higher BVAS at baseline (12 and 15 respectively). Patient 9 had infusions every 4 weeks because of the severity of his disease, but his BVAS at 6 months improved under this regimen (BVAS 4 vs 12).
For 8/10 patients, because immunosuppressants were not prescribed during the first 42 days, the reported improvements could be attributed to anti-TNF- Ab and CS. Nevertheless, immunosuppressants reintroduced after day 42 could have contributed to the beneficial effects seen at 6 months. The combination of immunosuppressant and infliximab is, however, recommended in order to prevent the synthesis of anti-chimeric antibodies.
In the present study, we observed only a minor and transitory effect during the first 2 months of treatment. A tolerance study conducted on WG patients showed good acceptance of anti-TNF- combined with therapies other than MTX [15].
We attempted to evaluate the effect of short-term infliximab in this study. At present we do not know if this anti-TNF- Ab can be considered a maintenance treatment or should be prescribed only to treat flares. Further studies are needed to answer this question.
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|